Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL), Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lens
Alcon Laboratories, LLC · Decision date Jan 7, 2020
What did the FDA approve?
FDA records P190018 as an original PMA application. The recorded decision is approval, dated Jan 7, 2020.
FDA approval order statement
Approval for the Clareon and Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lens (IOL).Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL):The Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL) is indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed. Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lens (IOL):The Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lenses (IOLs) are indicated for primary implantation in the capsular bag in the posterior chamber of the eye for visual correction of aphakia and pre-existing corneal astigmatism to reduce residual refractive cylinder and improve uncorrected distance vision in adult patients in whom a cataractous lens has been removed. Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL) with the AutonoMe Pre-loaded Delivery System:The Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL) is indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed. Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lens (IOL) with the AutonoMe Pre-loaded Delivery System:The Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lenses (IOLs) are indicated for primary implantation in the capsular bag in the posterior chamber of the eye for visual correction of aphakia and pre-existing corneal astigmatism to reduce residual refractive cylinder and improve uncorrected distance vision in adult patients in whom a cataractous lens has been removed.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ophthalmic
- Decision date
- Jan 7, 2020
Regulatory record facts
- Identifier
- P190018
- Regulatory pathway
- Premarket approval application
- Applicant
- Alcon Laboratories, LLC
- Product code
- HQL
- Decision code
- APPR
- Decision date
- Jan 7, 2020
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: intraocular lens.
- Applicant
- Alcon Laboratories, LLC
- Product code
- HQL
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P190018 received
Application receipt date recorded by FDA.
P190018 · FDA decision
APPR
P190018/S050 · Related supplement
Clareon Vivity Pro Extended Vision IOLs
Timeline entries are records held by MedtechLedger for P190018. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190018
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Clareon Vivity Pro Extended Vision IOLsP190018/S050 | Alcon Laboratories, LLC | PMA supplement | Oct 30, 2026 | FDA |
Explore the linked device profile
Other records with product code HQL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FINEVISION HP Trifocal IOLsP240038/S004 | Beaver-Visitec International, Inc. | PMA supplement | Oct 27, 2026 | FDA |
CT LUCIA Intraocular Lenses (IOLs)P100016/S028 | Carl Zeiss Meditec Production, LLC | PMA supplement | Oct 23, 2026 | FDA |
enVista Hydrophobic Acrylic Intraocular LensP910056/S067 | Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Alcon Laboratories, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6201 S. Fwy., Fort Worth, TX, 76134
Sources and methodology
- Original FDA record: P190018
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



